These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 11956072)

  • 41. Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia.
    Nägler DK; Krüger S; Kellner A; Ziomek E; Menard R; Buhtz P; Krams M; Roessner A; Kellner U
    Prostate; 2004 Jul; 60(2):109-19. PubMed ID: 15162377
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy.
    Carswell BM; Woda BA; Wang X; Li C; Dresser K; Jiang Z
    Histopathology; 2006 May; 48(6):668-73. PubMed ID: 16681682
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Value of new prostate cancer markers: alpha methylacyl CoA racemase (P504S) and p63].
    Molinié V; Hervé JM; Lugagne PM; Yonneau L; Ellard S; Lebret T; Botto H
    Prog Urol; 2005 Sep; 15(4):611-5. PubMed ID: 16459672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium.
    Lisovsky M; Falkowski O; Bhuiya T
    Hum Pathol; 2006 Dec; 37(12):1601-6. PubMed ID: 16996568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Evaluation of p63 and p504s markers for the diagnosis of prostate cancer].
    Molinié V; Vieillefond A; Michiels JF;
    Ann Pathol; 2008 Oct; 28(5):417-23. PubMed ID: 19068396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation].
    Pozharisskiĭ KM; Leenman EE; Arzumanov AA
    Arkh Patol; 2005; 67(5):15-9. PubMed ID: 16323473
    [TBL] [Abstract][Full Text] [Related]  

  • 48. alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
    Santinelli A; Mazzucchelli R; Barbisan F; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R
    Am J Clin Pathol; 2007 Oct; 128(4):657-66. PubMed ID: 17875519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations.
    Shah RB; Kunju LP; Shen R; LeBlanc M; Zhou M; Rubin MA
    Am J Clin Pathol; 2004 Oct; 122(4):517-23. PubMed ID: 15487448
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p63 expression profile in normal and malignant prostate epithelial cells.
    Davis LD; Zhang W; Merseburger A; Young D; Xu L; Rhim JS; Moul JW; Srivastava S; Sesterhenn IA
    Anticancer Res; 2002; 22(6C):3819-25. PubMed ID: 12553000
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New molecular markers for prostate tumor imaging: a study on 2-methylene substituted fatty acids as new AMACR inhibitors.
    Morgenroth A; Urusova EA; Dinger C; Al-Momani E; Kull T; Glatting G; Frauendorf H; Jahn O; Mottaghy FM; Reske SN; Zlatopolskiy BD
    Chemistry; 2011 Aug; 17(36):10144-50. PubMed ID: 21812041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk: a replication study in an ethnically homogeneous population.
    FitzGerald LM; Thomson R; Polanowski A; Patterson B; McKay JD; Stankovich J; Dickinson JL
    Prostate; 2008 Sep; 68(13):1373-9. PubMed ID: 18537123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.
    Zielie PJ; Mobley JA; Ebb RG; Jiang Z; Blute RD; Ho SM
    J Urol; 2004 Sep; 172(3):1130-3. PubMed ID: 15311056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?
    Zhou M; Aydin H; Kanane H; Epstein JI
    Am J Surg Pathol; 2004 Feb; 28(2):239-43. PubMed ID: 15043314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. p63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning.
    Hameed O; Humphrey PA
    Am J Clin Pathol; 2005 Nov; 124(5):708-15. PubMed ID: 16203278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
    Lee WA
    Oncology; 2006; 71(3-4):246-50. PubMed ID: 17652945
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Virtual microscopy in prostate histopathology: simultaneous viewing of biopsies stained sequentially with hematoxylin and eosin, and alpha-methylacyl-coenzyme A racemase/p63 immunohistochemistry.
    Helin HO; Lundin ME; Laakso M; Lundin J; Helin HJ; Isola J
    J Urol; 2006 Feb; 175(2):495-9. PubMed ID: 16406979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The value of triple antibody (34βE12 + p63 + AMACR) cocktail stain in radical prostatectomy specimens with crushed surgical margins.
    Daoud NA; Li G; Evans AJ; van der Kwast TH
    J Clin Pathol; 2012 May; 65(5):437-40. PubMed ID: 22294716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
    Zhou M; Chinnaiyan AM; Kleer CG; Lucas PC; Rubin MA
    Am J Surg Pathol; 2002 Jul; 26(7):926-31. PubMed ID: 12131161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
    Cossu-Rocca P; Contini M; Brunelli M; Festa A; Pili F; Gobbo S; Eccher A; Mura A; Massarelli G; Martignoni G
    Am J Surg Pathol; 2009 Jul; 33(7):1031-6. PubMed ID: 19384190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.